Non-Invasive Diagnostics Fueling ABUS Market Insights 2033

The global automated breast ultrasound system (ABUS) market, valued at USD 1.7 billion in 2023, is projected to reach USD 4.3 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.7%. ABUS, including automated breast ultrasound systems and automated breast volume scanners (ABVS), enhances breast cancer detection in dense breast tissues, offering precise, non-invasive diagnostics. The market is driven by rising breast cancer prevalence, with 85% of cases originating in ducts and 15% in lobules, per the World Health Organization, and increasing awareness of early screening. North America holds a dominant 50% market share, fueled by advanced healthcare infrastructure and public-private investments in cancer awareness.

Challenges include a shortage of trained radiologists, high system costs, and false-positive biopsy risks. Innovations, such as Siemens’ ACUSON S2000 ABVS with 3D imaging and Hitachi’s SOFIA scanner, address limitations of traditional ultrasound, boosting accuracy. The shift from radiography to ABUS in diagnostic centers and growing demand for minimally invasive diagnostics, especially in hospitals, support market expansion. With technological advancements and early diagnosis trends, the ABUS market is poised for robust growth through 2033.

For more insights into the Market, Request a Sample of this Report:

https://www.factmr.com/connectus/sample?flag=S&rep_id=585

Market Analysis

The ABUS market is propelled by the global rise in breast cancer, the second leading cause of cancer-related deaths in women, and technological advancements improving detection accuracy. ABVS, holding a 50% market share, are favored for real-time imaging and rapid, painless scans, enhancing early detection. The integration of ABUS with full-field digital mammography (FFDM) provides higher-quality imaging, driving adoption in dense breast screening. Government initiatives promoting early diagnosis and increasing healthcare spending, particularly in North America, fuel demand. Hospitals lead end-user segments due to the need for safe diagnostics for pregnant women, who cannot undergo mammography.

Challenges include economic instability, limited investment in new equipment, and regulatory hurdles restricting supply in some regions. The shortage of radiologists trained in ultrasound imaging and high costs compared to traditional screening methods hinder growth. Trends include a shift to automated systems from handheld devices, addressing prolonged screening times, and innovations targeting dense breast tissues. The market’s growth is supported by rising consumer awareness, especially among women aged 62 and older, and the expansion of diagnostic centers adopting ABUS for reliable lesion detection through 2033.

Segment Analysis

The ABUS market is segmented by product, end user, and region. Automated breast volume scanners, with a 50% share, dominate products due to their ability to analyze lactiferous ducts and provide volumetric imaging with high-frequency ultrasound. Hospitals lead end users, driven by the growing use of ABUS for pregnant women and routine screening among young and middle-aged women. Diagnostic centers follow, adopting ABUS to replace radiography and MRI for early-stage cancer detection. North America, with a 50% share, leads regionally, followed by Europe and Asia-Pacific, where hospital partnerships and medical tourism drive growth.

Country-wise Insights

In the United States, the market grows due to government programs raising breast cancer awareness and demand for advanced imaging technologies. Germany’s market is driven by favorable insurance policies, established healthcare infrastructure, and rising demand for non-invasive diagnostics. Japan sees growth from increased hospital and diagnostic center investments, high R&D spending, and medical tourism. These countries benefit from urbanization, consumer healthcare spending, and technological advancements, positioning them as key markets through 2033.

Key Players

GE Healthcare
SuperSonic Imagine SA
Volpara Solutions Limited
CapeRay Medical
MetriTrack Inc.
SonoCiné Inc.
Delphinus Medical Technologies Inc.
Siemens AG
Hitachi Ltd.

Strategic Outlook and Industry Trends

The ABUS market is evolving through technological innovation and regulatory compliance. Trends include the integration of ABUS with FFDM for enhanced imaging and the development of 3D-capable systems like Siemens’ ACUSON S2000 ABVS. Companies focus on installing ABUS in hospitals and diagnostic centers, adhering to safety standards to minimize environmental impact. Innovations address conventional ultrasound limitations, such as prolonged scanning times, boosting consumer acceptance. Strategic partnerships with hospitals and R&D investments in accurate, minimally invasive diagnostics will drive market growth through 2033.

Segmentation of Automated Breast Ultrasound System Market

By Product: